ANKRD55: A new gene involved in Multiple Sclerosis is discovered

May 27, 2016

Multiple Sclerosis (MS) is a neurological disease, characterised by demyelination and the onset of chronic, neurodegenerative damage of the central nervous system. Right now, its causes are unknown although various self-immune mechanisms are known to be involved.

The research community is already aware that genetic variants lead to changes in the code of the DNA component and that in order to understand their biological effects, the effects of the expression of the corresponding gene need to be studied, in other words, the changes in the messenger RNA and the proteins.

The Neurogenomiks research group, linked to the Achucarro Basque Centre for Neuroscience (EHUgroup) and the University of the Basque Country (UPV/EHU), has just had a research article published in the prestigious scientific publication Journal of Immunology; it details how they have managed to show that the gene known as ANKRD55 produces 3 different transcripts of the messenger RNA, and that the genetic variant associated with MS greatly increases the production of these transcripts.

The lead author of this research, the Ikerbasque researcher Dr Koen Vandenbroeck, stressed that "we have also discovered and proven that this takes place specifically in the case of a particular category of immune cells, the so-called T CD4+ cells. This suggests that ANKRD55 exerts a significant biological function on these cells and which now needs to be deciphered. It is important to point out that the region of the 5qll chromosome contains various known genes that play a role in immune response. Nevertheless, our data clearly point to ANKRD55 as the key gene in this area.

T CD4+ cells are crucially important in generating protective cell immune responses and they are thought to be deregulated in multiple sclerosis. This study concludes that the ANKRD55 gene may play a fundamental role in this deregulation.

Apart from that, the team has managed to show that the ANKRD55 proteins reside in the nuclei of the cells, and that suggests that they could play a significant role in the specific processes that take place in the cell nucleus such as gene transcription. This work, which has been done in collaboration with the group of Dr Carmen Guaza of the Instituto Cajal in Madrid, and Dr X. Montalban and Dr M. Comabella of the Val d'Hebron Institut de Recerca in Barcelona, constitutes a significant advance in the understanding of the biology of the ANKRD55 gene and of the proteins it expresses, given that a new player has been discovered in the neuro-inflammation process that takes place in Multiple Sclerosis. So the results of this study will strengthen an in-depth study of ANKRD55, with the ultimate aim of opening up diagnostic and therapeutic means to benefit patients who suffer from MS.
-end-
Bibliographical reference

A. Lopez de Lapuente et al. "Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55". The Journal of Immunology. May 4, 2016 1501205 doi: 10.4049/jimmunol.1501205

University of the Basque Country

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.